M. Brun

Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis.

Luca Richeldi, G. Raghu, A. Nicholson, 2011, The New England journal of medicine.

Treatment Of IPF With The Tyrosine Kinase Inhibitor BIBF 1120: Patient-Reported Outcomes In The TOMORROW Trial

G. Raghu, H. Staines, M. Selman, 2012, ATS 2012.

Effect of tiotropium on health-related quality of life as a primary efficacy endpoint in COPD

T. Perez, M. Brun, A. Tonnel, 2008, International journal of chronic obstructive pulmonary disease.

Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.

H. Collard, G. Raghu, A. Nicholson, 2014, The New England journal of medicine.

Validity, reliability, and responsiveness of a new shortVisual Simplified Respiratory Questionnaire (VSRQ©) for health-related quality of life assessment in chronic obstructive pulmonary disease

T. Perez, B. Arnould, I. Guillemin, 2008, International journal of chronic obstructive pulmonary disease.

Validity, reliability, and responsiveness of a new shortVisual Simplified Respiratory Questionnaire (VSRQ©) for health-related quality of life assessment in chronic obstructive pulmonary disease

T. Perez, B. Arnould, I. Guillemin, 2009, International journal of chronic obstructive pulmonary disease.

Validity , reliability , and responsiveness of a new short Visual Simpli fi ed Respiratory Questionnaire ( VSRQ © ) for health-related quality of life assessment in chronic obstructive pulmonary disease

T. Perez, B. Arnould, I. Guillemin, 2008 .

Rationale and design of the EMPERIAL‐Preserved and EMPERIAL‐Reduced trials of empagliflozin in patients with chronic heart failure

Akshay S. Desai, G. Filippatos, J. Butler, 2019, European journal of heart failure.

Efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis: Results of two 52-week, Phase III, randomized, placebo-controlled trials (INPULSIS™)

H. Collard, G. Raghu, H. Taniguchi, 2015 .